# Jean A Boutin

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 258 papers | 8,494 citations | 47 h-index | 79 g-index |
| 268 ext. papers | 9,239 ext. citations | 5.3 avg, IF | 5.82 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 258 | Caloxin-derived peptides for the inhibition of plasma membrane calcium ATPases. *Peptides*, **2022**, 154, 170813 | 3.8 | 0 |
| 257 | A putative new melatonin binding site in sheep brain, MTx: preliminary observations and characteristics. *Journal of Pharmacology and Experimental Therapeutics*, **2021**, | 4.7 | 1 |
| 256 | Further assessments of ligase LplA-mediated modifications of proteins in vitro and in cellulo. *Molecular Biology Reports*, **2021**, 1 | 2.8 | |
| 255 | Feature-Based Molecular Network-Guided Dereplication of Natural Bioactive Products from Leaves of (Willd.) Hochr. *Metabolites*, **2021**, 11, | 5.6 | 2 |
| 254 | Apigenin and Luteolin Regulate Autophagy by Targeting NRH-Quinone Oxidoreductase 2 in Liver Cells. *Antioxidants*, **2021**, 10, | 7.1 | 2 |
| 253 | Association of NQO2 With UDP-Glucuronosyltransferases Reduces Menadione Toxicity in Neuroblastoma Cells. *Frontiers in Pharmacology*, **2021**, 12, 660641 | 5.6 | 0 |
| 252 | Biochemistry, structure, and cellular internalization of a four nanobody-bearing Fc dimer. *Protein Science*, **2021**, 30, 1946-1957 | 6.3 | 1 |
| 251 | Chemical composition and antibacterial action of Stryphnodendron pulcherrimum bark extract, Barbatimão species: Evaluation of its use as a topical agent. *Arabian Journal of Chemistry*, **2021**, 14, 103183 | 5.9 | 3 |
| 250 | Journal of pineal research guideline for authors: Defining and characterizing melatonin targets. *Journal of Pineal Research*, **2021**, 70, e12712 | 10.4 | 6 |
| 249 | Melatonin controversies, an update. *Journal of Pineal Research*, **2021**, 70, e12702 | 10.4 | 10 |
| 248 | MCH-R1 Antagonist GPS18169, a Pseudopeptide, Is a Peripheral Anti-Obesity Agent in Mice. *Molecules*, **2021**, 26, | 4.8 | 1 |
| 247 | Identification of catalytic and non-catalytic activity inhibitors against PRC2-EZH2 complex through multiple high-throughput screening campaigns. *Chemical Biology and Drug Design*, **2020**, 96, 1024-1051 | 2.9 | 3 |
| 246 | Melatonin receptor ligands: A pharmaco-chemical perspective. *Journal of Pineal Research*, **2020**, 69, e12672 | 10.4 | 18 |
| 245 | Unraveling Plant Natural Chemical Diversity for Drug Discovery Purposes. *Frontiers in Pharmacology* , **2020**, 11, 397 | 5.6 | 61 |
| 244 | VHH characterization.Recombinant VHHs: Production, characterization and affinity. *Analytical Biochemistry*, **2020**, 589, 113491 | 3.1 | 4 |
| 243 | Characterization of the various functional pathways elicited by synthetic agonists or antagonists at the melatonin MT and MT receptors. *Pharmacology Research and Perspectives*, **2020**, 8, e00539 | 3.1 | 16 |
| 242 | The five dimensions of receptor pharmacology exemplified by melatonin receptors: An opinion. *Pharmacology Research and Perspectives*, **2020**, 8, e00556 | 3.1 | 13 |

| | | | |
|---|---|---|---|
| 241 | Molecular Pharmacology of NRH:Quinone Oxidoreductase 2: A Detoxifying Enzyme Acting as an Undercover Toxifying Enzyme. *Molecular Pharmacology*, **2020**, 98, 620-633 | 4.3 | 12 |
| 240 | Secure and Sustainable Sourcing of Plant Tissues for the Exhaustive Exploration of Their Chemodiversity. *Molecules*, **2020**, 25, | 4.8 | 2 |
| 239 | General lack of structural characterization of chemically synthesized long peptides. *Protein Science*, **2019**, 28, 857-867 | 6.3 | 5 |
| 238 | Fluorescent analogues of BeKm-1 with high and specific activity against the hERG channel. *Toxicon: X*, **2019**, 2, 100010 | 2.6 | 2 |
| 237 | The PINK1 kinase-driven ubiquitin ligase Parkin promotes mitochondrial protein import through the presequence pathway in living cells. *Scientific Reports*, **2019**, 9, 11829 | 4.9 | 29 |
| 236 | VHH characterization. Comparison of recombinant with chemically synthesized anti-HER2 VHH. *Protein Science*, **2019**, 28, 1865-1879 | 6.3 | 7 |
| 235 | Importance of the Choice of a Recombinant System to Produce Large Amounts of Functional Membrane Protein hERG. *International Journal of Molecular Sciences*, **2019**, 20, | 6.3 | 6 |
| 234 | Antimalarial Properties of Dunnione Derivatives as NQO2 Substrates. *Molecules*, **2019**, 24, | 4.8 | 4 |
| 233 | S29434, a Quinone Reductase 2 Inhibitor: Main Biochemical and Cellular Characterization. *Molecular Pharmacology*, **2019**, 95, 269-285 | 4.3 | 9 |
| 232 | Is There Sufficient Evidence that the Melatonin Binding Site Is Quinone Reductase 2?. *Journal of Pharmacology and Experimental Therapeutics*, **2019**, 368, 59-65 | 4.7 | 39 |
| 231 | A structural study of the complex between neuroepithelial cell transforming gene 1 (Net1) and RhoA reveals a potential anticancer drug hot spot. *Journal of Biological Chemistry*, **2018**, 293, 9064-9077 | 5.4 | 4 |
| 230 | GHSR-D2R heteromerization modulates dopamine signaling through an effect on G protein conformation. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, 4501-4506 | 11.5 | 45 |
| 229 | Oxidative stress and neurodegeneration: The possible contribution of quinone reductase 2. *Free Radical Biology and Medicine*, **2018**, 120, 56-61 | 7.8 | 20 |
| 228 | A Chemical Library to Screen Protein and Protein□igand Crystallization Using a Versatile Microfluidic Platform. *Crystal Growth and Design*, **2018**, 18, 5130-5137 | 3.5 | 16 |
| 227 | Characterization of the Mel1c melatoninergic receptor in platypus (Ornithorhynchus anatinus). *PLoS ONE*, **2018**, 13, e0191904 | 3.7 | 19 |
| 226 | Assessments of cellular melatonin receptor signaling pathways: □arrestin recruitment, receptor internalization, and impedance variations. *European Journal of Pharmacology*, **2018**, 818, 534-544 | 5.3 | 15 |
| 225 | On the Organization of a Drug Discovery Platform **2018**, | | 1 |
| 224 | How Can Molecular Pharmacology Help Understand the Multiple Actions of Melatonin: 20 Years of Research and Trends **2018**, | | 5 |

| | | | |
|---|---|---|---|
| 223 | Hamster Melatonin Receptors: Cloning and Binding Characterization of MT and Attempt to Clone MT *International Journal of Molecular Sciences*, **2018**, 19, | 6.3 | 7 |
| 222 | Design, Synthesis, Molecular Dynamics Simulation, and Functional Evaluation of a Novel Series of 26RFa Peptide Analogues Containing a Mono- or Polyalkyl Guanidino Arginine Derivative. *Journal of Medicinal Chemistry*, **2018**, 61, 10185-10197 | 8.3 | 2 |
| 221 | Gene expression profiling during hibernation in the European hamster. *Scientific Reports*, **2018**, 8, 13167 | 4.9 | 10 |
| 220 | Natural Inhibitors of the RhoA-p115 Complex from the Bark of Meiogyne baillonii. *Journal of Natural Products*, **2018**, 81, 1610-1618 | 4.9 | 5 |
| 219 | Microfluidic platform for optimization of crystallization conditions. *Journal of Crystal Growth*, **2017**, 472, 18-28 | 1.6 | 22 |
| 218 | W2476 ameliorates cell dysfunction and exerts therapeutic effects in mouse models of diabetes via modulation of the thioredoxin-interacting protein signaling pathway. *Acta Pharmacologica Sinica*, **2017**, 38, 1024-1037 | 8 | 7 |
| 217 | Cryo-electron microscopy and X-ray crystallography: complementary approaches to structural biology and drug discovery. *Acta Crystallographica Section F, Structural Biology Communications*, **2017**, 73, 174-183 | 1.1 | 37 |
| 216 | New quinolinic derivatives as melatonergic ligands: Synthesis and pharmacological evaluation. *European Journal of Medicinal Chemistry*, **2017**, 127, 621-631 | 6.8 | 6 |
| 215 | Screening ubiquitin specific protease activities using chemically synthesized ubiquitin and ubiquitinated peptides. *Analytical Biochemistry*, **2017**, 519, 57-70 | 3.1 | 4 |
| 214 | Binding mode prediction and MD/MMPBSA-based free energy ranking for agonists of REV-ERB NCoR. *Journal of Computer-Aided Molecular Design*, **2017**, 31, 755-775 | 4.2 | 18 |
| 213 | Crystallization via tubing microfluidics permits both in situ and ex situ X-ray diffraction. *Acta Crystallographica Section F, Structural Biology Communications*, **2017**, 73, 574-578 | 1.1 | 11 |
| 212 | Role of Quinone Reductase 2 in the Antimalarial Properties of Indolone-Type Derivatives. *Molecules* , **2017**, 22, | 4.8 | 7 |
| 211 | New MT Melatonin Receptor-Selective Ligands: Agonists and Partial Agonists. *International Journal of Molecular Sciences*, **2017**, 18, | 6.3 | 12 |
| 210 | Alternative Radioligands for Investigating the Molecular Pharmacology of Melatonin Receptors. *Journal of Pharmacology and Experimental Therapeutics*, **2016**, 356, 681-92 | 4.7 | 21 |
| 209 | Melatonergic ligands: Design, synthesis and pharmacological evaluation of novel series of naphthofuranic derivatives. *European Journal of Medicinal Chemistry*, **2016**, 109, 360-70 | 6.8 | 5 |
| 208 | Detergent-free Isolation of Functional G Protein-Coupled Receptors into Nanometric Lipid Particles. *Biochemistry*, **2016**, 55, 38-48 | 3.2 | 73 |
| 207 | Quinone reductase 2 as a promising target of melatonin therapeutic actions. *Expert Opinion on Therapeutic Targets*, **2016**, 20, 303-17 | 6.4 | 48 |
| 206 | Molecular Dynamics Simulations and Kinetic Measurements to Estimate and Predict Protein-Ligand Residence Times. *Journal of Medicinal Chemistry*, **2016**, 59, 7167-76 | 8.3 | 61 |

| | | | |
|---|---|---|---|
| 205 | High-throughput drug profiling with voltage- and calcium-sensitive fluorescent probes in human iPSC-derived cardiomyocytes. *American Journal of Physiology - Heart and Circulatory Physiology*, **2016**, 311, H44-53 | 5.2 | 54 |
| 204 | Total chemical synthesis, refolding, and crystallographic structure of fully active immunophilin calstabin 2 (FKBP12.6). *Protein Science*, **2016**, 25, 2225-2242 | 6.3 | 6 |
| 203 | Piceatannol and resveratrol share inhibitory effects on hydrogen peroxide release, monoamine oxidase and lipogenic activities in adipose tissue, but differ in their antilipolytic properties. *Chemico-Biological Interactions*, **2016**, 258, 115-25 | 5 | 27 |
| 202 | □F nuclear magnetic resonance screening of glucokinase activators. *Analytical Biochemistry*, **2015**, 477, 62-8 | 3.1 | 8 |
| 201 | Highly Potent and Selective MT2 Melatonin Receptor Full Agonists from Conformational Analysis of 1-Benzyl-2-acylaminomethyl-tetrahydroquinolines. *Journal of Medicinal Chemistry*, **2015**, 58, 7512-25 | 8.3 | 31 |
| 200 | In cellulo monitoring of quinone reductase activity and reactive oxygen species production during the redox cycling of 1,2 and 1,4 quinones. *Free Radical Biology and Medicine*, **2015**, 89, 126-34 | 7.8 | 29 |
| 199 | Synthesis and pharmacological evaluation of dual ligands for melatonin (MT1/MT2) and serotonin 5-HT2C receptor subtypes (II). *European Journal of Medicinal Chemistry*, **2015**, 90, 822-33 | 6.8 | 8 |
| 198 | Molecular mechanisms of transcriptional control by Rev-erb□An energetic foundation for reconciling structure and binding with biological function. *Protein Science*, **2015**, 24, 1129-46 | 6.3 | 7 |
| 197 | Synthesis, chiral resolution, absolute configuration assignment and pharmacological evaluation of a series of melatoninergic ligands. *MedChemComm*, **2014**, 5, 1303-1308 | 5 | 3 |
| 196 | New melatonin (MT1/MT2) ligands: design and synthesis of (8,9-dihydro-7H-furo[3,2-f]chromen-1-yl) derivatives. *Bioorganic and Medicinal Chemistry*, **2014**, 22, 986-96 | 3.4 | 16 |
| 195 | Recombinant human melatonin receptor MT1 isolated in mixed detergents shows pharmacology similar to that in mammalian cell membranes. *PLoS ONE*, **2014**, 9, e100616 | 3.7 | 18 |
| 194 | Melatonin MT□and MT□receptors display different molecular pharmacologies only in the G-protein coupled state. *British Journal of Pharmacology*, **2014**, 171, 186-201 | 8.6 | 41 |
| 193 | Molecular basis of agonist docking in a human GPR103 homology model by site-directed mutagenesis and structure-activity relationship studies. *British Journal of Pharmacology*, **2014**, 171, 4425-39 | 8.6 | 8 |
| 192 | Melatonin from cerebrospinal fluid but not from blood reaches sheep cerebral tissues under physiological conditions. *Journal of Neuroendocrinology*, **2014**, 26, 151-63 | 3.8 | 47 |
| 191 | Synthesis and pharmacological evaluation of a series of the agomelatine analogues as melatonin MT1 /MT2 agonist and 5-HT2C antagonist. *ChemMedChem*, **2013**, 8, 1830-45 | 3.7 | 15 |
| 190 | New radioligands for describing the molecular pharmacology of MT1 and MT2 melatonin receptors. *International Journal of Molecular Sciences*, **2013**, 14, 8948-62 | 6.3 | 26 |
| 189 | S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab. *Molecular Cancer Therapeutics*, **2013**, 12, 1749-62 | 6.1 | 69 |
| 188 | High-throughput screening for GPR119 modulators identifies a novel compound with anti-diabetic efficacy in db/db mice. *PLoS ONE*, **2013**, 8, e63861 | 3.7 | 11 |

| | | | |
|---|---|---|---|
| 187 | Characterization of cofactors, substrates and inhibitor binding to flavoenzyme quinone reductase 2 by automated supramolecular nano-electrospray ionization mass spectrometry. *International Journal of Mass Spectrometry*, **2012**, 312, 87-96 | 1.9 | 11 |
| 186 | Design, synthesis and pharmacological evaluation of new series of naphthalenic analogues as melatoninergic (MT1/MT2) and serotoninergic 5-HT2C dual ligands (I). *European Journal of Medicinal Chemistry*, **2012**, 49, 310-23 | 6.8 | 25 |
| 185 | Molecular pharmacology of the mouse melatonin receptors MT and MT *European Journal of Pharmacology*, **2012**, 677, 15-21 | 5.3 | 23 |
| 184 | Effect of oxime ether incorporation in acyl indole derivatives on PPAR subtype selectivity. *ChemMedChem*, **2012**, 7, 2179-93 | 3.7 | 12 |
| 183 | Rational design of a low molecular weight, stable, potent, and long-lasting GPR103 aza- -pseudopeptide agonist. *Journal of Medicinal Chemistry*, **2012**, 55, 7516-24 | 8.3 | 22 |
| 182 | Mutagenic analysis in a pure molecular system shows that thioredoxin-interacting protein residue Cys247 is necessary and sufficient for a mixed disulfide formation with thioredoxin. *Protein Science*, **2012**, 21, 1323-33 | 6.3 | 3 |
| 181 | Description of the constitutive activity of cloned human melatonin receptors hMT(1) and hMT(2) and discovery of inverse agonists. *Journal of Pineal Research*, **2012**, 53, 29-37 | 10.4 | 17 |
| 180 | Peripheral injections of melanin-concentrating hormone receptor 1 antagonist S38151 decrease food intake and body weight in rodent obesity models. *Frontiers in Endocrinology*, **2012**, 3, 160 | 5.7 | 9 |
| 179 | S32212, a novel serotonin type 2C receptor inverse agonist/ -adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization. *Journal of Pharmacology and Experimental Therapeutics*, **2012**, 340, 750-64 | 4.7 | 12 |
| 178 | Insights into the redox cycle of human quinone reductase 2. *Free Radical Research*, **2011**, 45, 1184-95 | 4 | 41 |
| 177 | Characterization of novel checkpoint kinase 1 inhibitors by in vitro assays and in human cancer cells treated with topoisomerase inhibitors. *Life Sciences*, **2011**, 89, 259-68 | 6.8 | 9 |
| 176 | The RFamide neuropeptide 26RFa and its role in the control of neuroendocrine functions. *Frontiers in Neuroendocrinology*, **2011**, 32, 387-97 | 8.9 | 43 |
| 175 | Synthesis and pharmacological evaluation of thieno[2,3-b]pyridine derivatives as novel c-Src inhibitors. *Bioorganic and Medicinal Chemistry*, **2011**, 19, 2517-28 | 3.4 | 55 |
| 174 | The active conformation of human glucokinase is not altered by allosteric activators. *Acta Crystallographica Section D: Biological Crystallography*, **2011**, 67, 929-35 | | 45 |
| 173 | X-ray structural studies of quinone reductase 2 nanomolar range inhibitors. *Protein Science*, **2011**, 20, 1182-95 | 6.3 | 36 |
| 172 | Structure-activity relationships of a series of analogues of the RFamide-related peptide 26RFa. *Journal of Medicinal Chemistry*, **2011**, 54, 4806-14 | 8.3 | 28 |
| 171 | Design and synthesis of 1-(2-alkanamidoethyl)-6-methoxy-7-azaindole derivatives as potent melatonin agonists. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 2316-9 | 2.9 | 14 |
| 170 | Design and synthesis of naphthalenic derivatives as new ligands at the melatonin binding site MT3. *European Journal of Medicinal Chemistry*, **2011**, 46, 1622-9 | 6.8 | 11 |

| | | | |
|---|---|---|---|
| 169 | Preparation and pharmacological evaluation of a novel series of 2-(phenylthio)benzo[b]thiophenes as selective MT2 receptor ligands. *European Journal of Medicinal Chemistry*, **2011**, 46, 1835-40 | 6.8 | 20 |
| 168 | Genetic deletion of trace amine 1 receptors reveals their role in auto-inhibiting the actions of ecstasy (MDMA). *Journal of Neuroscience*, **2011**, 31, 16928-40 | 6.6 | 66 |
| 167 | A quantitative assay for lysosomal acidification rates in human osteoclasts. *Assay and Drug Development Technologies*, **2011**, 9, 157-64 | 2.1 | 3 |
| 166 | Specific oncogenic activity of the Src-family tyrosine kinase c-Yes in colon carcinoma cells. *PLoS ONE* , **2011**, 6, e17237 | 3.7 | 32 |
| 165 | Molecular and cellular pharmacological properties of 5-methoxycarbonylamino-N-acetyltryptamine (MCA-NAT): a nonspecific MT3 ligand. *Journal of Pineal Research*, **2010**, 48, 222-229 | 10.4 | 32 |
| 164 | Expression of the orphan GPR50 protein in rodent and human dorsomedial hypothalamus, tanycytes and median eminence. *Journal of Pineal Research*, **2010**, 48, 263-269 | 10.4 | 47 |
| 163 | Loss of quinone reductase 2 function selectively facilitates learning behaviors. *Journal of Neuroscience*, **2010**, 30, 12690-700 | 6.6 | 34 |
| 162 | Meganuclease-driven targeted integration in CHO-K1 cells for the fast generation of HTS-compatible cell-based assays. *Journal of Biomolecular Screening*, **2010**, 15, 956-67 | | 25 |
| 161 | Synthesis of new 8(S)-HETE analogs and their biological evaluation as activators of the PPAR nuclear receptors. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2010**, 25, 653-72 | 5.6 | 2 |
| 160 | Receptor- and ligand-based study on novel 2,2'-bithienyl derivatives as non-peptidic AANAT inhibitors. *Journal of Chemical Information and Modeling*, **2010**, 50, 446-60 | 6.1 | 2 |
| 159 | Design, synthesis and pharmacological evaluation of novel naphthalenic derivatives as selective MT(1) melatoninergic ligands. *Bioorganic and Medicinal Chemistry*, **2010**, 18, 3426-36 | 3.4 | 21 |
| 158 | Screening of protein kinase inhibitors identifies PKC inhibitors as inhibitors of osteoclastic acid secretion and bone resorption. *BMC Musculoskeletal Disorders*, **2010**, 11, 250 | 2.8 | 13 |
| 157 | Old and new inhibitors of quinone reductase 2. *Chemico-Biological Interactions*, **2010**, 186, 103-9 | 5 | 39 |
| 156 | Autotaxin. *Cellular and Molecular Life Sciences*, **2009**, 66, 3009-21 | 10.3 | 37 |
| 155 | The end of a myth: cloning and characterization of the ovine melatonin MT(2) receptor. *British Journal of Pharmacology*, **2009**, 158, 1248-62 | 8.6 | 50 |
| 154 | 4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARalpha/gamma agonists. Part. II: Synthesis and pharmacological evaluation of oxime and acidic head group structural variations. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 2683-7 | 2.9 | 14 |
| 153 | Design and synthesis of 3-phenyltetrahydronaphthalenic derivatives as new selective MT2 melatoninergic ligands. Part II. *Bioorganic and Medicinal Chemistry*, **2009**, 17, 2963-74 | 3.4 | 14 |
| 152 | A Dimeric sesquiterpenoid from a Malaysian Meiogyne as a new inhibitor of Bcl-xL/BakBH3 domain peptide interaction. *Journal of Natural Products*, **2009**, 72, 480-3 | 4.9 | 36 |

| | | | |
|---|---|---|---|
| 151 | Image-free assessment of protein translocation in live cells. *Current Opinion in Pharmacology*, **2009**, 9, 650-6 | 5.1 | 3 |
| 150 | S38151 [p-guanidinobenzoyl-[Des-Gly(10)]-MCH(7-17)] is a potent and selective antagonist at the MCH(1) receptor and has anti-feeding properties in vivo. *Peptides*, **2009**, 30, 1997-2007 | 3.8 | 9 |
| 149 | Binding kinetics of glucose and allosteric activators to human glucokinase reveal multiple conformational states. *Biochemistry*, **2009**, 48, 5466-82 | 3.2 | 44 |
| 148 | Cytotoxic pentacyclic triterpenoids from Combretum sundaicum and Lantana camara as inhibitors of Bcl-xL/BakBH3 domain peptide interaction. *Journal of Natural Products*, **2009**, 72, 1314-20 | 4.9 | 28 |
| 147 | Melatonin receptors, heterodimerization, signal transduction and binding sites: what's new?. *British Journal of Pharmacology*, **2008**, 154, 1182-95 | 8.6 | 202 |
| 146 | Molecular cloning and pharmacological characterization of rat melatonin MT1 and MT2 receptors. *Biochemical Pharmacology*, **2008**, 75, 2007-19 | 6 | 39 |
| 145 | Molecular pharmacology of adipocyte-secreted autotaxin. *Chemico-Biological Interactions*, **2008**, 172, 115-24 | 5 | 15 |
| 144 | Studies of the melatonin binding site location onto quinone reductase 2 by directed mutagenesis. *Archives of Biochemistry and Biophysics*, **2008**, 477, 12-9 | 4.1 | 13 |
| 143 | A generic approach for the purification of signaling complexes that specifically interact with the carboxyl-terminal domain of G protein-coupled receptors. *Molecular and Cellular Proteomics*, **2008**, 7, 1556-69 | 7.6 | 30 |
| 142 | Murine and human autotaxin alpha, beta, and gamma isoforms: gene organization, tissue distribution, and biochemical characterization. *Journal of Biological Chemistry*, **2008**, 283, 7776-89 | 5.4 | 91 |
| 141 | S32826, a nanomolar inhibitor of autotaxin: discovery, synthesis and applications as a pharmacological tool. *Journal of Pharmacology and Experimental Therapeutics*, **2008**, 327, 809-19 | 4.7 | 82 |
| 140 | Kinetic, thermodynamic and X-ray structural insights into the interaction of melatonin and analogues with quinone reductase 2. *Biochemical Journal*, **2008**, 413, 81-91 | 3.8 | 74 |
| 139 | Synthesis of potential Rho-kinase inhibitors based on the chemistry of an original heterocycle: 4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one. *European Journal of Medicinal Chemistry*, **2008**, 43, 1730-6 | 6.8 | 9 |
| 138 | Synthesis of 3-phenylnaphthalenic derivatives as new selective MT(2) melatoninergic ligands. *Bioorganic and Medicinal Chemistry*, **2008**, 16, 8339-48 | 3.4 | 19 |
| 137 | 4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARalpha/gamma agonists. Part I: synthesis and pharmacological evaluation. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 1617-22 | 2.9 | 34 |
| 136 | High-throughput screening of novel antagonists on melanin-concentrating hormone receptor-1. *Acta Pharmacologica Sinica*, **2008**, 29, 752-8 | 8 | 14 |
| 135 | High-throughput screening assay for new ligands at human melatonin receptors. *Acta Pharmacologica Sinica*, **2008**, 29, 1515-21 | 8 | 11 |
| 134 | MT3/QR2 melatonin binding site does not use melatonin as a substrate or a co-substrate. *Journal of Pineal Research*, **2008**, 45, 524-31 | 10.4 | 32 |

| | | | |
|---|---|---|---|
| 133 | Synthesis of a Novel Series of 8-HETE Analogs and their Biological Evaluation Towards the PPAR Nuclear Receptors. *Letters in Drug Design and Discovery*, **2008**, 5, 503-511 | 0.8 | 3 |
| 132 | Use-dependent inhibition of hHCN4 by ivabradine and relationship with reduction in pacemaker activity. *British Journal of Pharmacology*, **2007**, 150, 37-46 | 8.6 | 78 |
| 131 | Detection of the human GPR50 orphan seven transmembrane protein by polyclonal antibodies mapping different epitopes. *Journal of Pineal Research*, **2007**, 43, 10-5 | 10.4 | 18 |
| 130 | Functional invalidation of the autotaxin gene by a single amino acid mutation in mouse is lethal. *FEBS Letters*, **2007**, 581, 3572-8 | 3.8 | 51 |
| 129 | S18986: a positive modulator of AMPA-receptors enhances (S)-AMPA-mediated BDNF mRNA and protein expression in rat primary cortical neuronal cultures. *European Journal of Pharmacology*, **2007**, 561, 23-31 | 5.3 | 17 |
| 128 | Resistance to high-fat-diet-induced obesity and sexual dimorphism in the metabolic responses of transgenic mice with moderate uncoupling protein 3 overexpression in glycolytic skeletal muscles. *Diabetologia*, **2007**, 50, 2190-9 | 10.3 | 43 |
| 127 | Comment on "Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake". *Science*, **2007**, 315, 766; author reply 766 | 33.3 | 151 |
| 126 | Cellular knock-down of quinone reductase 2: a laborious road to successful inhibition by RNA interference. *Biochimie*, **2007**, 89, 1264-75 | 4.6 | 15 |
| 125 | A simple theoretical model for fluorescence polarization binding assay development. *Journal of Biomolecular Screening*, **2006**, 11, 949-58 | | 19 |
| 124 | Therapeutic potential of melatonin ligands. *Chronobiology International*, **2006**, 23, 413-8 | 3.6 | 40 |
| 123 | Expression of UCP3 in CHO cells does not cause uncoupling, but controls mitochondrial activity in the presence of glucose. *Biochemical Journal*, **2006**, 393, 431-9 | 3.8 | 42 |
| 122 | The use of IRES-based bicistronic vectors allows the stable expression of recombinant G-protein coupled receptors such as NPY5 and histamine 4. *Biochimie*, **2006**, 88, 737-46 | 4.6 | 11 |
| 121 | A microplate assay for the screening of ADAMTS-4 inhibitors. *Matrix Biology*, **2006**, 25, 261-7 | 11.4 | 6 |
| 120 | New ligands at the melatonin binding site MT(3). *European Journal of Medicinal Chemistry*, **2006**, 41, 306-28 | 2.8 | 73 |
| 119 | Assessment of a high-throughput screening methodology for the measurement of purified UCP1 uncoupling activity. *Analytical Biochemistry*, **2006**, 351, 201-6 | 3.1 | 8 |
| 118 | Covalent binding of 15-deoxy-delta12,14-prostaglandin J2 to PPARgamma. *Biochemical and Biophysical Research Communications*, **2005**, 337, 521-5 | 3.4 | 36 |
| 117 | Molecular tools to study melatonin pathways and actions. *Trends in Pharmacological Sciences*, **2005**, 26, 412-9 | 13.2 | 177 |
| 116 | Molecular evidence that melatonin is enzymatically oxidized in a different manner than tryptophan: investigations with both indoleamine 2,3-dioxygenase and myeloperoxidase. *Biochemical Journal*, **2005**, 388, 205-15 | 3.8 | 60 |

| | | | |
|---|---|---|---|
| 115 | Quinone reductase 2 substrate specificity and inhibition pharmacology. *Chemico-Biological Interactions*, **2005**, 151, 213-28 | 5 | 44 |
| 114 | Functional characterization of human neuropeptide Y receptor subtype five specific antagonists using a luciferase reporter gene assay. *Cellular Signalling*, **2005**, 17, 489-96 | 4.9 | 5 |
| 113 | NRH:quinone reductase 2: an enzyme of surprises and mysteries. *Biochemical Pharmacology*, **2005**, 71, 1-12 | 6 | 119 |
| 112 | Characterization of the melatoninergic MT3 binding site on the NRH:quinone oxidoreductase 2 enzyme. *Biochemical Pharmacology*, **2005**, 71, 74-88 | 6 | 98 |
| 111 | Potential involvement of adipocyte insulin resistance in obesity-associated up-regulation of adipocyte lysophospholipase D/autotaxin expression. *Diabetologia*, **2005**, 48, 569-77 | 10.3 | 87 |
| 110 | The emergence of selective 5-HT 2B antagonists structures, activities and potential therapeutic applications. *Mini-Reviews in Medicinal Chemistry*, **2004**, 4, 325-30 | 3.2 | 25 |
| 109 | Design and synthesis of indole and tetrahydroisoquinoline hydantoin derivatives as human chymase inhibitors. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2004**, 19, 137-43 | 5.6 | 8 |
| 108 | A potent and selective NPY Y5 antagonist reduces food intake but not through blockade of the NPY Y5 receptor. *International Journal of Obesity*, **2004**, 28, 628-39 | 5.5 | 17 |
| 107 | Molecular pharmacology of the ovine melatonin receptor: comparison with recombinant human MT1 and MT2 receptors. *Biochemical Pharmacology*, **2004**, 67, 667-77 | 6 | 34 |
| 106 | New substrate analogues of human serotonin N-acetyltransferase produce in situ specific and potent inhibitors. *FEBS Journal*, **2004**, 271, 418-28 | | 14 |
| 105 | Preparation of 4-azaindole and 7-azaindole dimers with a bisalkoxyalkyl spacer in order to preferentially target melatonin MT1 receptors over melatonin MT2 receptors. *European Journal of Medicinal Chemistry*, **2004**, 39, 515-26 | 6.8 | 27 |
| 104 | Organs from mice deleted for NRH:quinone oxidoreductase 2 are deprived of the melatonin binding site MT3. *FEBS Letters*, **2004**, 578, 116-20 | 3.8 | 62 |
| 103 | Purification of the recombinant human serotonin N-acetyltransferase (EC 2.3.1.87): further characterization of and comparison with AANAT from other species. *Protein Expression and Purification*, **2004**, 38, 84-98 | 2 | 14 |
| 102 | Comparative analysis of melanin-concentrating hormone structure and activity in fishes and mammals. *Peptides*, **2004**, 25, 1623-32 | 3.8 | 18 |
| 101 | Peroxisome proliferator-activated receptor gamma (PPARgamma ) as a molecular target for the soy phytoestrogen genistein. *Journal of Biological Chemistry*, **2003**, 278, 962-7 | 5.4 | 248 |
| 100 | Autotaxin is released from adipocytes, catalyzes lysophosphatidic acid synthesis, and activates preadipocyte proliferation. Up-regulated expression with adipocyte differentiation and obesity. *Journal of Biological Chemistry*, **2003**, 278, 18162-9 | 5.4 | 175 |
| 99 | Post-translational modification of Bid has differential effects on its susceptibility to cleavage by caspase 8 or caspase 3. *Journal of Biological Chemistry*, **2003**, 278, 15749-57 | 5.4 | 60 |
| 98 | Design, synthesis and in vitro evaluation of novel benzo[b]thiophene derivatives as serotonin N-acetyltransferase (AANAT) inhibitors. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2003**, 18, 119-25 | 5.6 | 10 |

| | | | |
|---|---|---|---|
| 97 | Synthesis of 5-substituted-2,3-dihydro-1,4-benzoxathiins: biological evaluation as melatonin receptors ligands. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2003**, 18, 187-93 | 5.6 | 8 |
| 96 | Molecular identification of the long isoform of the human neuropeptide Y Y5 receptor and pharmacological comparison with the short Y5 receptor isoform. *Biochemical Journal*, **2003**, 369, 667-73 | 3.8 | 17 |
| 95 | New selective ligands of human cloned melatonin MT1 and MT2 receptors. *Naunyn-Schmiedebergs Archives of Pharmacology*, **2003**, 367, 553-61 | 3.4 | 198 |
| 94 | Synthesis of new arylalkoxy amido derivatives as melatoninergic ligands. *Bioorganic and Medicinal Chemistry*, **2003**, 11, 789-800 | 3.4 | 9 |
| 93 | Jean - Luc Fauchere (1941?2003). *Chemical Biology and Drug Design*, **2003**, 62, 185-185 | | |
| 92 | Therapeutic perspectives for melatonin agonists and antagonists. *Journal of Neuroendocrinology*, **2003**, 15, 442-8 | 3.8 | 52 |
| 91 | Endothelin-1 inhibits TNF alpha-induced iNOS expression in 3T3-F442A adipocytes. *British Journal of Pharmacology*, **2003**, 139, 935-44 | 8.6 | 13 |
| 90 | Design and synthesis of 3-phenyl tetrahydronaphthalenic derivatives as new selective MT2 melatoninergic ligands. *Bioorganic and Medicinal Chemistry*, **2003**, 11, 753-9 | 3.4 | 36 |
| 89 | Design and synthesis of naphthalenic dimers as selective MT1 melatoninergic ligands. *Journal of Medicinal Chemistry*, **2003**, 46, 1127-9 | 8.3 | 59 |
| 88 | In vivo characterisation of the human UCP3 gene minimal promoter in mice tibialis anterior muscles. *Biochemical and Biophysical Research Communications*, **2003**, 311, 583-91 | 3.4 | 8 |
| 87 | Natural ligands of PPARgamma: are prostaglandin J(2) derivatives really playing the part?. *Cellular Signalling*, **2002**, 14, 573-83 | 4.9 | 117 |
| 86 | Ligand modulation of [35S]GTPgammaS binding at human alpha(2A), alpha(2B) and alpha(2C) adrenoceptors. *Cellular Signalling*, **2002**, 14, 829-37 | 4.9 | 24 |
| 85 | Characterization and regulation of a CHO cell line stably expressing human serotonin N-acetyltransferase (EC 2.3.1.87). *Cellular and Molecular Life Sciences*, **2002**, 59, 1395-405 | 10.3 | 15 |
| 84 | Design, synthesis and in vitro evaluation of novel derivatives as serotonin N-acetyltransferase inhibitors. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2002**, 17, 409-14 | 5.6 | 11 |
| 83 | Uncoupling protein-3 (UCP3) mRNA expression in reconstituted human muscle after myoblast transplantation in RAG2-/-/gamma c/C5(-) immunodeficient mice. *Journal of Biological Chemistry*, **2002**, 277, 47407-11 | 5.4 | 14 |
| 82 | Appetite-boosting property of pro-melanin-concentrating hormone(131-165) (neuropeptide-glutamic acid-isoleucine) is associated with proteolytic resistance. *Journal of Pharmacology and Experimental Therapeutics*, **2002**, 302, 766-73 | 4.7 | 22 |
| 81 | Synthesis of nitroindole derivatives with high affinity and selectivity for melatoninergic binding sites MT(3). *Journal of Medicinal Chemistry*, **2002**, 45, 1853-9 | 8.3 | 35 |
| 80 | Synthesis and structure-affinity-activity relationships of novel benzofuran derivatives as MT(2) melatonin receptor selective ligands. *Journal of Medicinal Chemistry*, **2002**, 45, 2788-800 | 8.3 | 79 |

| | | | |
|---|---|---|---|
| 79 | Melanin-concentrating hormone and its receptors: state of the art. *Canadian Journal of Physiology and Pharmacology*, **2002**, 80, 388-95 | 2.4 | 44 |
| 78 | SVK14 cells express an MCH binding site different from the MCH1 or MCH2 receptor. *Biochemical and Biophysical Research Communications*, **2002**, 295, 841-8 | 3.4 | 11 |
| 77 | Expression and regulation of the nuclear receptor RORalpha in human vascular cells. *FEBS Letters*, **2002**, 511, 36-40 | 3.8 | 42 |
| 76 | Parallel synthesis and pharmacological screening of nonpeptide ligands of the neuropeptide Y receptor subtype Y5. *Chemical Biology and Drug Design*, **2001**, 57, 419-27 | | 2 |
| 75 | From peptide libraries to optimized nonpeptide ligands in the search for S-farnesyltransferase inhibitors. *Chemical Biology and Drug Design*, **2001**, 57, 85-96 | | 1 |
| 74 | Development of new assays and improved procedures for the purification of recombinant human chymase. *FEBS Journal*, **2001**, 268, 5885-93 | | 5 |
| 73 | [125I]-S36057: a new and highly potent radioligand for the melanin-concentrating hormone receptor. *British Journal of Pharmacology*, **2001**, 133, 371-8 | 8.6 | 37 |
| 72 | Comparative pharmacological studies of melatonin receptors: MT1, MT2 and MT3/QR2. Tissue distribution of MT3/QR2. *Biochemical Pharmacology*, **2001**, 61, 1369-79 | 6 | 155 |
| 71 | Binding of prostaglandins to human PPARgamma: tool assessment and new natural ligands. *European Journal of Pharmacology*, **2001**, 417, 77-89 | 5.3 | 44 |
| 70 | Structure-activity relationship studies of melanin-concentrating hormone (MCH)-related peptide ligands at SLC-1, the human MCH receptor. *Journal of Biological Chemistry*, **2001**, 276, 13554-62 | 5.4 | 55 |
| 69 | Role of a pineal cAMP-operated arylalkylamine N-acetyltransferase/14-3-3-binding switch in melatonin synthesis. *Proceedings of the National Academy of Sciences of the United States of America* , **2001**, 98, 8083-8 | 11.5 | 150 |
| 68 | Structure and expression of the human histamine H4-receptor gene. *Biochemical and Biophysical Research Communications*, **2001**, 284, 301-9 | 3.4 | 120 |
| 67 | Regulation of murine airway responsiveness by endothelial nitric oxide synthase. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2001**, 281, L258-67 | 5.8 | 31 |
| 66 | Genomic organization and characterization of splice variants of the human histamine H3 receptor. *Biochemical Journal*, **2001**, 355, 279-88 | 3.8 | 67 |
| 65 | SLC-1 receptor mediates effect of melanin-concentrating hormone on feeding behavior in rat: a structure-activity study. *Journal of Pharmacology and Experimental Therapeutics*, **2001**, 299, 137-46 | 4.7 | 30 |
| 64 | Cloning and molecular characterization of the novel human melanin-concentrating hormone receptor MCH2. *Molecular Pharmacology*, **2001**, 60, 632-9 | 4.3 | 78 |
| 63 | Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states. *Synapse*, **2000**, 35, 79-95 | 2.4 | 141 |
| 62 | Synthesis of a small library of phenylalkylamide derivatives as melatoninergic ligands for human mt1 and MT2 receptors. *Bioorganic and Medicinal Chemistry*, **2000**, 8, 163-71 | 3.4 | 13 |

| | | | |
|---|---|---|---|
| 61 | Synthesis of phenalene and acenaphthene derivatives as new conformationally restricted ligands for melatonin receptors. *Journal of Medicinal Chemistry*, **2000**, 43, 4051-62 | 8.3 | 32 |
| 60 | Antagonist properties of the novel antipsychotic, S16924, at cloned, human serotonin 5-HT2C receptors: a parallel phosphatidylinositol and calcium accumulation comparison with clozapine and haloperidol. *Naunyn-Schmiedebergs Archives of Pharmacology*, **2000**, 361, 549-54 | 3.4 | 5 |
| 59 | Screening of ligand binding on melatonin receptor using non-peptide combinatorial libraries. *Journal of Receptor and Signal Transduction Research*, **2000**, 20, 105-18 | 2.6 | 5 |
| 58 | Substrate specificity and inhibition studies of human serotonin N-acetyltransferase. *Journal of Biological Chemistry*, **2000**, 275, 8794-805 | 5.4 | 46 |
| 57 | High-capacity screening of arylalkylamine N-acetyltransferase inhibitors using a high-performance liquid chromatography system. *Journal of Biomolecular Screening*, **2000**, 5, 361-8 | | 8 |
| 56 | Identification of the melatonin-binding site MT3 as the quinone reductase 2. *Journal of Biological Chemistry*, **2000**, 275, 31311-7 | 5.4 | 397 |
| 55 | Food intake regulation in rodents: Y5 or Y1 NPY receptors or both?. *Canadian Journal of Physiology and Pharmacology*, **2000**, 78, 173-185 | 2.4 | 52 |
| 54 | Food intake regulation in rodents: Y5 or Y1 NPY receptors or both?. *Canadian Journal of Physiology and Pharmacology*, **2000**, 78, 173-185 | 2.4 | 30 |
| 53 | Physico-chemical and biological analysis of true combinatorial libraries. *Biomedical Applications*, **1999**, 725, 17-37 | | 11 |
| 52 | NPY receptor subtype in the rabbit isolated ileum. *British Journal of Pharmacology*, **1999**, 127, 795-801 | 8.6 | 30 |
| 51 | Investigation of S-farnesyl transferase substrate specificity with combinatorial tetrapeptide libraries. *Cellular Signalling*, **1999**, 11, 59-69 | 4.9 | 19 |
| 50 | Cloning and characterization of the 5' flanking region of the human uncoupling protein 3 (UCP3) gene. *Biochemical and Biophysical Research Communications*, **1999**, 258, 278-83 | 3.4 | 95 |
| 49 | Truncated isoforms inhibit [3H]prazosin binding and cellular trafficking of native human 1A-adrenoceptors. *Biochemical Journal*, **1999**, 343, 231 | 3.8 | 25 |
| 48 | Characterization of 2-[125I]iodomelatonin binding sites in Syrian hamster peripheral organs. *Journal of Pharmacology and Experimental Therapeutics*, **1999**, 290, 334-40 | 4.7 | 50 |
| 47 | A zinc chelator inhibiting gelatinases exerts potent in vitro anti-invasive effects. *European Journal of Pharmacology*, **1998**, 351, 225-33 | 5.3 | 9 |
| 46 | Combinatorial chemistry for the generation of molecular diversity and the discovery of bioactive leads. *Chemometrics and Intelligent Laboratory Systems*, **1998**, 43, 43-68 | 3.8 | 25 |
| 45 | NPY receptor subtypes involved in the contraction of the proximal colon of the rat. *Regulatory Peptides*, **1998**, 75-76, 221-9 | | 30 |
| 44 | Chromatographic assay and peptide substrate characterization of partially purified farnesyl- and geranylgeranyltransferases from rat brain cytosol. *Archives of Biochemistry and Biophysics*, **1998**, 354, 83-94 | 4.1 | 10 |

| | | | |
|---|---|---|---|
| 43 | Peptide and nonpeptide lead discovery using robotically synthesized soluble libraries. *Canadian Journal of Physiology and Pharmacology*, **1997**, 75, 683-689 | 2.4 | 8 |
| 42 | Myristoylation. *Cellular Signalling*, **1997**, 9, 15-35 | 4.9 | 330 |
| 41 | Limitations of the coupling of amino acid mixtures for the preparation of equimolar peptide libraries. *Molecular Diversity*, **1997**, 3, 43-60 | 3.1 | 17 |
| 40 | Selection of a histidine-containing inhibitor of gelatinases through deconvolution of combinatorial tetrapeptide libraries. *Molecular Diversity*, **1997**, 2, 135-46 | 3.1 | 28 |
| 39 | Evaluation of high performance liquid chromatography/electrospray mass spectrometry with selected ion monitoring for the analysis of large synthetic combinatorial peptide libraries. *Rapid Communications in Mass Spectrometry*, **1997**, 11, 1971-1976 | 2.2 | 18 |
| 38 | Peptide and nonpeptide lead discovery using robotically synthesized soluble libraries. *Canadian Journal of Physiology and Pharmacology*, **1997**, 75, 683-9 | 2.4 | 3 |
| 37 | Combinatorial peptide synthesis: statistical evaluation of peptide distribution. *Trends in Pharmacological Sciences*, **1996**, 17, 8-12 | 13.2 | 17 |
| 36 | Combinatorial peptide libraries: robotic synthesis and analysis by nuclear magnetic resonance, mass spectrometry, tandem mass spectrometry, and high-performance capillary electrophoresis techniques. *Analytical Biochemistry*, **1996**, 234, 126-41 | 3.1 | 57 |
| 35 | Tyrosine protein kinase assays. *Biomedical Applications*, **1996**, 684, 179-99 | | 7 |
| 34 | Substrate phosphorylation capacities of the major tyrosine protein kinase from the human promyelocytic cell line, HL-60. *International Journal of Peptide and Protein Research*, **1994**, 43, 496-504 | | 8 |
| 33 | Heterogeneity of hepatic microsomal UDP-glucuronosyltransferase(s) activities: a new kinetic approach for the study of induction and specificity. *Journal of Pharmaceutical Sciences*, **1994**, 83, 591-6 | 3.9 | 3 |
| 32 | Tyrosine protein kinase inhibition and cancer. *International Journal of Biochemistry & Cell Biology*, **1994**, 26, 1203-26 | | 51 |
| 31 | Heterogeneity of hepatic UDP-glucuronosyltransferase activities: investigations of isoenzymes involved in p-nitrophenol glucuronidation. *Comparative Biochemistry and Physiology C, Comparative Pharmacology and Toxicology*, **1993**, 106, 241-8 | | 5 |
| 30 | Purification and characterization of the major tyrosine protein kinase from the human promyelocytic cell line, HL60. *FEBS Journal*, **1993**, 214, 503-14 | | 10 |
| 29 | Myristoyl-CoA:protein N-myristoyltransferase activity in cancer cells. Purification and characterization of a cytosolic isoform from the murine leukemia cell line L1210. *FEBS Journal*, **1993** , 214, 853-67 | | 44 |
| 28 | Studies of the potency of protein kinase inhibitors on ATPase activities. *Chemico-Biological Interactions*, **1993**, 86, 17-27 | 5 | 14 |
| 27 | Integrated system for the screening of the specificity of protein kinase inhibitors. *Biochemical Pharmacology*, **1993**, 46, 439-48 | 6 | 21 |
| 26 | Relationship between the cellular accumulation and the cytotoxicity of S12363, a new Vinca alkaloid derivative. *Cancer Chemotherapy and Pharmacology*, **1992**, 29, 367-74 | 3.5 | 7 |

| | | | |
|---|---|---|---|
| 25 | Use of hydrophilic interaction chromatography for the study of tyrosine protein kinase specificity. *Biomedical Applications*, **1992**, 583, 137-43 | | 35 |
| 24 | N-myristoyl-transferase activity in cancer cells. Solubilization, specificity and enzymatic inhibition of a N-myristoyl transferase from L1210 microsomes. *FEBS Journal*, **1991**, 201, 257-63 | | 10 |
| 23 | New alpha-amino phosphonic acid derivatives of vinblastine: chemistry and antitumor activity. *Journal of Medicinal Chemistry*, **1991**, 34, 1998-2003 | 8.3 | 103 |
| 22 | Approaches to some biochemical mechanisms of action of tuftsin and analogues. *Biochemical Pharmacology*, **1991**, 41, 1411-8 | 6 | 7 |
| 21 | Assay of tyrosine protein kinase activity from HL-60 by high-performance liquid chromatography for specificity studies. *Analytical Biochemistry*, **1990**, 190, 32-8 | 3.1 | 16 |
| 20 | Use of the main tyrosine protein kinase activity purified from HL-60 in the search for a new class of anticancer compounds. *Anticancer Research*, **1990**, 10, 197-201 | 2.3 | 8 |
| 19 | Drug-induced hydrogen peroxide production in isolated rat hepatocytes. *Toxicology*, **1989**, 54, 129-37 | 4.4 | 13 |
| 18 | Effects of the new nitrosourea derivative, fotemustine, on the glutathione reductase activity in rat tissues in vivo and in isolated rat hepatocytes. *European Journal of Cancer & Clinical Oncology*, **1989**, 25, 1311-6 | | 16 |
| 17 | Partial purification and characterization of a new p36/40 tyrosine protein kinase from HL-60. *Biochemical and Biophysical Research Communications*, **1989**, 160, 1203-11 | 3.4 | 10 |
| 16 | Further validation of the Mulder and van Doorn kinetic procedure for the measurement of microsomal UDP-glucuronosyltransferase activities. *Biochemical Journal*, **1988**, 252, 930-1 | 3.8 | 10 |
| 15 | Indirect evidences of UDP-glucuronosyltransferase heterogeneity: how can it help purification?. *Drug Metabolism Reviews*, **1987**, 18, 517-51 | 7 | 17 |
| 14 | Heterogeneity of hepatic microsomal UDP-glucuronosyltransferases activities: use and comparison of differential inductions in some mammalian species. *Comparative Biochemistry and Physiology Part B: Comparative Biochemistry*, **1987**, 87, 513-22 | | 1 |
| 13 | In vitro evaluation of glucuronidation of monohydroxylated aglycones related to quantum chemically-calculated parameters. *European Journal of Medicinal Chemistry*, **1987**, 22, 393-402 | 6.8 | 6 |
| 12 | Liquid chromatographic assay for the measurement of glucuronidation of arylcarboxylic acids using uridine diphospho-[U-14C] glucuronic acid. *Biomedical Applications*, **1986**, 383, 51-60 | | 9 |
| 11 | Camphoroquinone reduction: another reaction catalyzed by rat liver cytosol 3 alpha-hydroxysteroid dehydrogenase. *BBA - Proteins and Proteomics*, **1986**, 870, 463-72 | | 17 |
| 10 | Rat liver microsomal 3 alpha-hydroxysteroid dehydrogenase and dihydrodiol dehydrogenase: solubilization, separation and partial purification. *Biochemical and Biophysical Research Communications*, **1986**, 135, 795-801 | 3.4 | 8 |
| 9 | Inhibition of microsomal NAD(P)H oxidation by Triton X-100. *Journal of Proteomics*, **1986**, 13, 171-8 | | 10 |
| 8 | UDP-glucuronosyltransferase(s) activities towards natural substrates in rat liver microsomes. Kinetic properties and influence of triton X-100 activation. *Pharmacological Research Communications*, **1985**, 17, 1005-15 | | 3 |

| | | | |
|---|---|---|---|
| 7 | Heterogeneity of hepatic microsomal UDP-glucuronosyltransferase activities. Conjugations of phenolic and monoterpenoid aglycones in control and induced rats and guinea pigs. *Biochemical Pharmacology*, **1985**, 34, 2235-49 | 6 | 66 |
| 6 | Heterogeneity of hepatic microsomal UDP-glucuronosyltransferase(s) activities: comparison between human and mammalian species activities. *Chemico-Biological Interactions*, **1984**, 52, 173-84 | 5 | 35 |
| 5 | Inhibition studies of microsomal UDP-glucuronosyltransferase activities by furosemide and salicylamide. *Pharmacological Research Communications*, **1984**, 16, 227-41 | | 16 |
| 4 | Assessment of the Mulder and Van Doorn kinetic procedure and rapid centrifugal analysis of UDP-glucuronosyltransferase activities. *Journal of Proteomics*, **1984**, 9, 69-79 | | 40 |
| 3 | Studies of UDP-glucuronosyltransferase activity toward eugenol, using a gas chromatographic method of measurement. *Analytical Biochemistry*, **1983**, 135, 201-7 | 3.1 | 17 |
| 2 | Effect of pretreatment with hydroxylated xenobiotics on the activities of rat liver UDP-glucuronosyl-transferases. *Xenobiotica*, **1983**, 13, 755-61 | 2 | 10 |
| 1 | UDP-glucuronosyltransferase activities in human liver microsomes and in some laboratory animal species. *Biochemical Pharmacology*, **1981**, 30, 2507-10 | 6 | 10 |